ASND
Price
$160.45
Change
+$2.31 (+1.46%)
Updated
Apr 24 closing price
Capitalization
9.65B
26 days until earnings call
LSTA
Price
$2.44
Change
+$0.09 (+3.83%)
Updated
Apr 24, 03:03 PM (EDT)
Capitalization
21.03M
12 days until earnings call
Ad is loading...

ASND vs LSTA

Header iconASND vs LSTA Comparison
Open Charts ASND vs LSTABanner chart's image
Ascendis Pharma A/S
Price$160.45
Change+$2.31 (+1.46%)
Volume$372.97K
Capitalization9.65B
Lisata Therapeutics
Price$2.44
Change+$0.09 (+3.83%)
Volume$163
Capitalization21.03M
ASND vs LSTA Comparison Chart
Loading...
ASND
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LSTA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ASND vs. LSTA commentary
Apr 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ASND is a StrongBuy and LSTA is a Buy.

Ad is loading...
COMPARISON
Comparison
Apr 25, 2025
Stock price -- (ASND: $160.45 vs. LSTA: $2.44)
Brand notoriety: ASND and LSTA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ASND: 71% vs. LSTA: 52%
Market capitalization -- ASND: $9.65B vs. LSTA: $21.03M
ASND [@Biotechnology] is valued at $9.65B. LSTA’s [@Biotechnology] market capitalization is $21.03M. The market cap for tickers in the [@Biotechnology] industry ranges from $275.91B to $0. The average market capitalization across the [@Biotechnology] industry is $2.09B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ASND’s FA Score shows that 0 FA rating(s) are green whileLSTA’s FA Score has 1 green FA rating(s).

  • ASND’s FA Score: 0 green, 5 red.
  • LSTA’s FA Score: 1 green, 4 red.
According to our system of comparison, ASND is a better buy in the long-term than LSTA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ASND’s TA Score shows that 7 TA indicator(s) are bullish while LSTA’s TA Score has 6 bullish TA indicator(s).

  • ASND’s TA Score: 7 bullish, 3 bearish.
  • LSTA’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, ASND is a better buy in the short-term than LSTA.

Price Growth

ASND (@Biotechnology) experienced а -2.79% price change this week, while LSTA (@Biotechnology) price change was +8.18% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +8.06%. For the same industry, the average monthly price growth was -5.30%, and the average quarterly price growth was -11.62%.

Reported Earning Dates

ASND is expected to report earnings on Sep 09, 2025.

LSTA is expected to report earnings on Aug 18, 2025.

Industries' Descriptions

@Biotechnology (+8.06% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ASND($9.65B) has a higher market cap than LSTA($21M). ASND YTD gains are higher at: 16.547 vs. LSTA (-18.121). LSTA has higher annual earnings (EBITDA): -22.24M vs. ASND (-290.02M). ASND has more cash in the bank: 560M vs. LSTA (31.2M). LSTA has less debt than ASND: LSTA (137K) vs ASND (857M). ASND has higher revenues than LSTA: ASND (364M) vs LSTA (1M).
ASNDLSTAASND / LSTA
Capitalization9.65B21M45,938%
EBITDA-290.02M-22.24M1,304%
Gain YTD16.547-18.121-91%
P/E RatioN/AN/A-
Revenue364M1M36,400%
Total Cash560M31.2M1,795%
Total Debt857M137K625,547%
FUNDAMENTALS RATINGS
ASND vs LSTA: Fundamental Ratings
ASND
LSTA
OUTLOOK RATING
1..100
126
VALUATION
overvalued / fair valued / undervalued
1..100
91
Overvalued
25
Undervalued
PROFIT vs RISK RATING
1..100
65100
SMR RATING
1..100
9994
PRICE GROWTH RATING
1..100
4474
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

LSTA's Valuation (25) in the null industry is significantly better than the same rating for ASND (91) in the Biotechnology industry. This means that LSTA’s stock grew significantly faster than ASND’s over the last 12 months.

ASND's Profit vs Risk Rating (65) in the Biotechnology industry is somewhat better than the same rating for LSTA (100) in the null industry. This means that ASND’s stock grew somewhat faster than LSTA’s over the last 12 months.

LSTA's SMR Rating (94) in the null industry is in the same range as ASND (99) in the Biotechnology industry. This means that LSTA’s stock grew similarly to ASND’s over the last 12 months.

ASND's Price Growth Rating (44) in the Biotechnology industry is in the same range as LSTA (74) in the null industry. This means that ASND’s stock grew similarly to LSTA’s over the last 12 months.

ASND's P/E Growth Rating (100) in the Biotechnology industry is in the same range as LSTA (100) in the null industry. This means that ASND’s stock grew similarly to LSTA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ASNDLSTA
RSI
ODDS (%)
Bullish Trend 1 day ago
73%
Bullish Trend 2 days ago
69%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 2 days ago
88%
Momentum
ODDS (%)
Bullish Trend 1 day ago
72%
Bullish Trend 2 days ago
75%
MACD
ODDS (%)
Bullish Trend 1 day ago
75%
Bullish Trend 2 days ago
81%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
68%
Bullish Trend 2 days ago
77%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
80%
Bearish Trend 2 days ago
86%
Advances
ODDS (%)
Bullish Trend 8 days ago
71%
Bullish Trend 2 days ago
78%
Declines
ODDS (%)
Bearish Trend 2 days ago
76%
Bearish Trend 14 days ago
87%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
68%
Bullish Trend 2 days ago
69%
Aroon
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 2 days ago
82%
View a ticker or compare two or three
Ad is loading...
ASND
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LSTA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
OEF264.965.81
+2.24%
iShares S&P 100 ETF
PDEC37.180.42
+1.14%
Innovator U.S. Eq Power Buffer ETF - Dec
HCRB34.900.18
+0.51%
Hartford Core Bond ETF
MMCA21.070.08
+0.41%
NYLI MacKay California Muni Intmdt ETF
DWUS45.44N/A
N/A
AdvisorShares DW FSM US Core ETF

ASND and

Correlation & Price change

A.I.dvisor indicates that over the last year, ASND has been loosely correlated with NUVL. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if ASND jumps, then NUVL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ASND
1D Price
Change %
ASND100%
+1.46%
NUVL - ASND
38%
Loosely correlated
+1.75%
ORMP - ASND
37%
Loosely correlated
-0.43%
AMRN - ASND
35%
Loosely correlated
+7.92%
AXON - ASND
34%
Loosely correlated
+2.39%
CASI - ASND
33%
Poorly correlated
+0.75%
More

LSTA and

Correlation & Price change

A.I.dvisor tells us that LSTA and RAIN have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that LSTA and RAIN's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LSTA
1D Price
Change %
LSTA100%
+3.63%
RAIN - LSTA
29%
Poorly correlated
+3.58%
HEPA - LSTA
26%
Poorly correlated
+2.11%
ASND - LSTA
26%
Poorly correlated
+1.46%
MRUS - LSTA
25%
Poorly correlated
+6.05%
AMLX - LSTA
25%
Poorly correlated
+3.56%
More